Navigation Links
Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting
Date:10/20/2009

id in the development of future clinical studies. We are grateful to the Juvenile Diabetes Research Foundation for their support and funding of our studies using this promising endpoint."

Details of Presentation of IENFD Data from SB-509-601 Study

Tuesday, October 20, 2009

  • "Epidermal nerve fiber density and regeneration with vascular endothelial growth factor zinc finger protein activator (SB-509) in mild to moderate diabetic peripheral neuropathy patients. (SB-509-0601 study)." M. Polydefkis(1), P. Haurei(1), *E. Benaim(2), D. Ando(2), S. Hamilton(2), H. Kim(2), S. Study Group(2); (1) Johns Hopkins Univ., Baltimore, MD; (2) Clin. Affairs, Sangamo BioSciences, Richmond, CA

IENFD and IENFD Regrowth (IENFDR) measurements were prospectively defined endpoints in Sangamo's double-blind, repeat dosing Phase 2 clinical study (SB-509-601) in which subjects were treated at 0, 60 and 120 days. Evaluation of SB-509 treatment on IENFD and IENFDR was carried out in collaboration with Michael Polydefkis, M.D., Associate Professor of Neurology, Johns Hopkins University Medical School and funded by a grant from the Juvenile Diabetes Research Foundation (JDRF).

IENFD derived from 3mm skin punch biopsies taken from the thigh at baseline (Day 0) and thirty days after the final treatment (Day 150) were obtained from both SB-509 and placebo treated subjects. In addition, IENFDR was determined by applying a capsaicin patch to the skin of the thigh to produce a standardized nerve injury on Days 150 and 151 and using serial skin biopsies over time, post capsaicin treatment, up to Day 360, to determine nerve regrowth in both SB-509 and placebo-treated subjects.

In SB-509 treated subjects an increase in mean change in nerve fiber density from baseline was observed compared to a decrease for placebo treated subjects (p-value = 0.02). Importantly, a rank sum analysis of these data
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
2. Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
3. Sangamo BioSciences Reports First Quarter 2009 Financial Results
4. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
5. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
6. Magellan Biosciences Sells its Life Sciences Tools Business to Dionex
7. Regado Biosciences Announces First Patient Enrolled in RADAR (Phase 2b) Study of REG1 Anticoagulation System
8. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
9. Cell Biosciences Launches Unique Protein Phosphorylation Assay Service
10. Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences(R) to Provide World-Class Fluid Management and Liquid/Powder System Solutions
11. Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... and industry leaders visited the New Jersey Institute ... Joel S. Bloom for the launch of the ... that provides a new model for business innovation ... education assets and investment. U.S. Senator Cory Booker, ... Joe Taylor, New Jersey Lieutenant Governor Kim Guadagno, ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... pregnancy among women using a newer method of planned ... greater over a 10-year period than using the more ... Yale University and UC Davis has found. , ... , the study found the higher risk of pregnancy ... name Essure. , "This study provides essential information ...
(Date:4/22/2014)... International Communication Association will hold its 64th annual ... of the 2014 conference will explore what the ... society. , Featuring over 2,300 academic papers on ... representing over 40 countries, the ICA conference is ... world. This year,s conference features sessions that focus ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... three of the 12 newly awarded grants from the ... prevention and treatment of prison and jail inmates. The ... are part of Seek, Test, and Treat: Addressing HIV ... initiative to date to aggressively identify and treat HIV-positive ...
... have hypertension are much more likely to have learning ... a new University of Rochester Medical Center (URMC) study ... In fact, when variables such as socio-economic levels are ... likely to have cognitive problems. "This ...
... Jenifer Goodwin HealthDay Reporter , MONDAY, Nov. 8 ... people who have never smoked may be a different disease ... genetic characteristics of lung cancer tumors in 30 people who ... The tumors of people who had never smoked had ...
... UC Davis researchers have found a new pathway for repairing ... week in the journal Proceedings of the National Academy ... greater capacity to repair oxidative damage," said Peter Beal, professor ... paper. As part of its inflammatory response, the body,s ...
... 2010) Results from a European Observational Study, ... at the Tenth International Congress on Drug Therapy ... of discontinuation and sustained virologic suppression with REYATAZ ... to five years. 1 The aim ...
... Multidetector computed tomography (CT) helps pinpoint the causes ... potentially speeding the delivery of life-saving treatments, according to ... of Radiology . "Our results suggest ... for identifying the cause of acute ischemic stroke," said ...
Cached Medicine News:Health News:Miriam receives $1.5 million from NIH to 'seek, test and treat' inmates with HIV 2Health News:Miriam receives $1.5 million from NIH to 'seek, test and treat' inmates with HIV 3Health News:Children with high blood pressure more likely to have learning disabilities 2Health News:Lung Cancer in Smokers, Nonsmokers May Be a Different Disease 2Health News:Lung Cancer in Smokers, Nonsmokers May Be a Different Disease 3Health News:New DNA repair pathway 2Health News:Study shows durable viral suppression of boosted REYATAZ in treatment-experienced HIV patients 2Health News:Using CT, radiologists can pinpoint cause of some strokes 2
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: ... the Office of Fair Trading (OFT) approval condition to the announced ... (NASDAQ: VPHM).   As a result of the waiver, ... expects to complete the tender offer on January 24, 2014 following ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Inc. (NASDAQ: VVUS ) today announced ... medical claims data on oral clefts (OC) associated ... study, known as FORTRESS for Fetal Outcome Retrospective ... to topiramate either alone (monotherapy) or in combination ...
... Dec. 21, 2011 Isentress (raltegravir) was approved today by ... antiretroviral drugs for the treatment of HIV-1 infection for children ... ) The drug is part of a ... works by slowing the spread of HIV in the body. ...
Cached Medicine Technology:VIVUS Reports Topline Findings From FORTRESS 2VIVUS Reports Topline Findings From FORTRESS 3VIVUS Reports Topline Findings From FORTRESS 4VIVUS Reports Topline Findings From FORTRESS 5VIVUS Reports Topline Findings From FORTRESS 6FDA Expands Use of HIV Drug Isentress to Children and Adolescents 2FDA Expands Use of HIV Drug Isentress to Children and Adolescents 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: